A Comparative Study of the Efficacy of Detach(R) Versus Zinc Oxide to Control Post-Weaning Diarrhoea in Piglets
Presents at Australasian Pig Science Association Conference
Sydney, Nov 21, 2017 AEST (ABN Newswire) - At the Australasian Pig Science Association (APSA) Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (
ASX:ANR) Detach(R) product to in-feed Zinc oxide (ZnO) in reducing diarrhoea and antibiotic treatments in post-weaning piglets. These results are significant given the push to remove ZnO from the food chain.
INTRODUCTION
Anatara Lifesciences is currently applying for re-registration of Detach(R) as an alternative to antibiotics and Zinc Oxide (ZnO) to aid in the control of pre- and post-weaning diarrhoea in piglets. Bromelain, the active in Detach(R) reduces diarrhoea through its anti-attachment and anti-secretory effect (see Notes 1, 2 below) on the intestine, and is therefore unlikely to contribute to antimicrobial resistance. This study was designed to compare the efficacy of a single 4mL Detach(R) drench at weaning (18-28 days of age) to ZnO (2,500 ppm in feed) as an aid in the control of post-weaning diarrhoea in piglets.
CONCLUSION
A single dose of Detach(R) at weaning was as effective as in-feed ZnO in reducing diarrhoea and antibiotic treatments in piglets post-weaning compared to untreated piglets.
Notes:
Literature Cited:
1 Chandler DS, Mynott TL (1998) Gut 43, 196-202;
2 Mynott TL, Guandalini S, Raimondi F, Fasano A (1997) Gastroenterology 113, 175-184
To view tables and figures, please visit:
http://abnnewswire.net/lnk/FRGS7B63
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
